Latest News

Study provides new analysis of isotretinoin and risk for adverse neuropsychiatric outcomes

Publish date: May 5, 2022

 

FROM THE BRITISH JOURNAL OF DERMATOLOGY

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Study eyes impact of isotretinoin on triglycerides, other lab measures
MDedge Pediatrics
Study estimates carbon footprint reduction of virtual isotretinoin visits
MDedge Pediatrics
FDA OKs iPLEDGE change for gender-neutral language
MDedge Pediatrics
Cannabinoids being studied for a variety of dermatologic conditions
MDedge Pediatrics
Topical options for acne patients continue to expand
MDedge Pediatrics
iPLEDGE rollout described as a failure, chaotic, and a disaster
MDedge Pediatrics
iPLEDGE rollout: As frustration mounts, FDA agrees to help solve issues
MDedge Pediatrics
FDA updates status of iPLEDGE access problems
MDedge Pediatrics
Questions about optimal dosing of isotretinoin persist, expert says
MDedge Pediatrics
Spironolactone not linked to increased cancer risk in systematic review and meta-analysis
MDedge Pediatrics